Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer's Mylotarg Finally Gets CHMP Nod But No New Indication For Sutent

Executive Summary

The EMA is finally set to approve Pfizer's targeted anticancer Mylotarg for use in acute myeloid leukemia. The company also received opinions for Bosulif and Sutent. 

You may also be interested in...



More Good News For AML As Pfizer And AbbVie/Roche Drugs Get FDA Okay

The options for AML are on the rise after no drugs for decades and the green lights for Daurismo and Venclexta mean that seven therapies for the disease have now been approved by the FDA since 2017.

More New EU Drug Approvals Bring Total For Year To 14

Seven new drugs were approved in the EU in the March-April period this year: TiGenix/Takeda's Alofisel, BioCryst's Alpivab, Chiesi's Lamzede, AstraZeneca's Lokelma, Pfizer's Mylotarg, GSK's Shingrix and MSD's Steglatro.

Six New Drugs Get EMA Nod, Radius and Portola To Fight Rejections

Two products that the European Medicines Agency this week said should not be authorized for sale in the EU are already approved in the US.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC100461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel